Management of Diabetic Gastroparesis

Nutrition in Clinical Practice

Volumn 19, Issue 2, 2004, Pages 145-153

  Jones, Michael P ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Galter Pavilion 4 104 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CYCLIZINE; DIMENHYDRINATE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOMPERIDONE; DRONABINOL; DROPERIDOL; ERYTHROMYCIN; GRANISETRON; HALOPERIDOL; LORAZEPAM; MECLOZINE; METOCLOPRAMIDE; OLANZAPINE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE MALEATE; PROKINETIC AGENT; PROMETHAZINE; SCOPOLAMINE; TEGASEROD; UNINDEXED DRUG;

ACUPRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DEVICE; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DROWSINESS; DRUG DEPENDENCE; DRUG TOLERANCE; ELECTROLYTE BALANCE; ELECTROSTIMULATION; EXTRAPYRAMIDAL SYMPTOM; FLUID BALANCE; GASTROSTOMY; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; JEJUNOSTOMY; MENTAL DISEASE; MOTION SICKNESS; NAUSEA; NUTRITIONAL STATUS; PARENTERAL NUTRITION; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; STOMACH EMPTYING; STOMACH PARESIS; SYMPTOMATOLOGY; TACHYPHYLAXIS; TREATMENT CONTRAINDICATION; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 1642504918     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426504019002145     Document Type: Review

References (50)

1. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989-1996.
2. Enck P, Rathmann W, Spiekermann M, et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol. 1994;32:637-641.
3. Ko GT, Chan WB, Chan JC, Tsang LW, Cockram CS. Gastrointestinal symptoms in Chinese patients with Type 2 diabetes mellitus. Diabet Med. 1999;16:670-674.
4. Maleki D, Locke GR 3rd, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160:2808-2816.
5. Talley N. Diabetic gastropathy and prokinetics. Am J Gastroenterol. 2003;98:264-271.
6. Verne GN, Sninsky CA. Diabetes and the gastrointestinal tract. Gastroenterol Clin North Am. 1998;27:861-874, vi-vii.
7. Ogorek CP, Davidson L, Fisher RS, Krevsky B. Idiopathic gastroparesis is associated with a multiplicity of severe dietary deficiencies. Am J Gastroenterol. 1991;86:423-428.
8. Devendra D, Millward BA, Travis SP. Diabetic gastroparesis improved by percutaneous endoscopic jejunostomy. Diabetes Care. 2000;23:426-427.
9. Jacober SJ, Narayan A, Strodel WE, Vinik AI. Jejunostomy feeding in the management of gastroparesis diabeticorum. Diabetes Care. 1986;9:217-219.
10. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol. 1996;91:2174-2178.
11. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc. 1998;47:67-70.
12. Michaud L, Guimber D, Carpentier B, et al. Gastrostomy as a decompression technique in children with chronic gastrointestinal obstruction. J Pediatr Gastroenterol Nutr. 2001;32:82-85.
13. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a sytematic review. Am J Gastroenterol. 2003;98:259-263.
14. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol. 2001;96:689-696.
15. Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer. 1997;33:1364-1370.
16. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163-173.
17. Matteson S, Roscoe J, Hickok J, Morrow GR. The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol. 2002;185(5 suppl):S239-S243.
18. Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin: a prospective randomized trial. Am J Clin Oncol. 1995;18:170-175.
19. Triozzi PL, Goldstein D, Laszlo J. Contributions of benzodiazepines to cancer therapy. Cancer Invest. 1988;6:103-111.
20. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16-21.
21. McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther. 1999;13:77-80.
22. Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage. 2003;25:578-582.
23. Alkaissi A, Evertsson K, Johnsson VA, Ofenbartl L, Kalman S. P6 acupressure may relieve nausea and vomiting after gynecological surgery: an effectiveness study in 410 women. Can J Anaesth. 2002;49:1034-1039.
24. White PF, Issioui T, Hu J, et al. Comparative efficacy of acustimulation (ReliefBand) versus ondansetron (Zofran) in combination with droperidol for preventing nausea and vomiting. Anesthesiology. 2002;97:1075-1081.
25. Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. Anesth Analg. 1999;88:1362-1369.
26. Hu S, Stritzel R, Chandler A, Stern RM. P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med. 1995;66:631-634.
27. Coloma M, White PF, Ogunnaike BO, et al. Comparison of acustimulation and ondansetron for the treatment of established postoperative nausea and vomiting. Anesthesiology. 2002;97:1387-1392.
28. Zarate E, Mingus M, White PF, et al. The use of transcutaneous acupoint electrical stimulation for preventing nausea and vomiting after laparoscopic surgery. Anesth Analg. 2001;92:629-635.
29. Pearl ML, Fischer M, McCauley DL, Valea FA, Chalas E. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. Cancer Nurs. 1999;22:307-311.
30. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med. 1983;98:86-95.
31. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33:429-440.
32. FDA Modernization Act of 1997. Section 503a.
33. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88:203-207.
34. Johnson AG. The effects of cisapride on antroduodenal co-ordination and gastric emptying. Scand J Gastroenterol Suppl. 1989;165:36-43.
35. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463-468.
36. Edmunds MC, Chen JD, Soykan I, Lin Z, McCallum RW. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998;12:167-174.
37. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461-1467.
38. Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol. 2002;97:1653-1660.
39. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc. 2002;55:920-923.
40. Karlstrom L, Kelly KA. Roux-Y gastrectomy for chronic gastric atony. Am J Surg. 1989;157:44-49.
41. McCallum RW, Polepalle SC, Schirmer B. Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease: long-term follow-up with subjective and objective parameters. Dig Dis Sci. 1991;36:1556-1561.
42. Forstner-Barthell AW, Murr MM, Nitecki S, et al. Near-total completion gastrectomy for severe postvagotomy gastric stasis: analysis of early and long-term results in 62 patients. J Gastrointest Surg. 1999;3:15-21.
43. Hinder RA, Esser J, DeMeester TR. Management of gastric emptying disorders following the Roux-en-Y procedure. Surgery. 1988;104:765-772.
44. Wooten RL, Meriweather TW. Diabetic gastric atony: a clinical study. JAMA. 1961;176:1082-1087.
45. Roon AJ, Mason GR. Surgical management of gastroparesis diabeticorum. CalifMed. 1972;116:58-61.
46. Shellito PC, Warshaw AL. Idiopathic intermittent gastroparesis and its surgical alleviation. Am J Surg. 1984;148:408-412.
47. Ejskjaer NT, Bradley JL, Buxton-Thomas MS, et al. Novel surgical treatment and gastric pathology in diabetic gastroparesis. Diabet Med. 1999;16:488-495.
48. US Food and Drug Administration. H990014-EnterraTM Therapy System (formerly named Gastric Electrical Stimulation (GES) System). Available at: http://www.fda.gov/cdrh/ode/H990014sum.html. Accessed November 25, 2003.
49. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125:421-428.
50. Koch K. Approach to the patient with nausea and vomiting. In: Yamada T, ed. Textbook of Gastroenterology. 2nd ed. Vol. 1. Philadelphia: J. B. Lippincott; 1995:731-749.